Crawford Research Institute, Shepherd Center, Atlanta, GA 30309 and Division of Physical Therapy, Emory University School of Medicine, Atlanta, GA 30322; 10Division of Preventive Medicin
Trang 1Medical Rehabilitation: Guidelines to Advance the Field with High-Impact Clinical
Trials
Marcas M Bamman, PhD, Gary R Cutter, PhD, David M Brienza, PhD, John Chae,
MD, Daniel M Corcos, PhD, Stephanie DeLuca, PhD, Edelle Field-Fote, PT, PhD,
Mona N Fouad, MD, MPH, Catherine E Lang, PT, PhD, Anne Lindblad, PhD, Robert
W Motl, PhD, Carla G Perna, CCRA, CCRP, Darcy Reisman, PT, PhD, Kenneth
M Saag, MD, MSc, Sean I Savitz, MD, Kathryn H Schmitz, MPH, PhD, Jennifer
Stevens-Lapsley, PT, PhD, John Whyte, MD, PhD, Carolee J Winstein, PT, PhD,
Mary E Michel, PhD
PII: S0003-9993(18)31113-4
DOI: 10.1016/j.apmr.2018.08.173
Reference: YAPMR 57345
To appear in: ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
Received Date: 31 December 2017
Revised Date: 11 July 2018
Accepted Date: 15 August 2018
Please cite this article as: Bamman MM, Cutter GR, Brienza DM, Chae J, Corcos DM, DeLuca S,Field-Fote E, Fouad MN, Lang CE, Lindblad A, Motl RW, Perna CG, Reisman D, Saag KM, Savitz SI,Schmitz KH, Stevens-Lapsley J, Whyte J, Winstein CJ, Michel ME, Medical Rehabilitation: Guidelines
to Advance the Field with High-Impact Clinical Trials, ARCHIVES OF PHYSICAL MEDICINE AND
REHABILITATION (2018), doi: 10.1016/j.apmr.2018.08.173
This is a PDF file of an unedited manuscript that has been accepted for publication As a service toour customers we are providing this early version of the manuscript The manuscript will undergocopyediting, typesetting, and review of the resulting proof before it is published in its final form Pleasenote that during the production process errors may be discovered which could affect the content, and alllegal disclaimers that apply to the journal pertain
Trang 2Running Head: Rehabilitation Clinical Trial Guidelines
Title: Medical Rehabilitation: Guidelines to Advance the Field with High-Impact Clinical Trials
Marcas M Bamman, PhD1,2,3, Gary R Cutter, PhD1,2,4, David M Brienza, PhD5, John Chae, MD6, Daniel M Corcos, PhD7, Stephanie DeLuca, PhD8, Edelle Field-Fote, PT, PhD9, Mona N Fouad, MD, MPH1,10,
Catherine E Lang, PT, PhD11, Anne Lindblad, PhD12, Robert W Motl, PhD1,2,13, Carla G Perna, CCRA, CCRP1,2, Darcy Reisman, PT, PhD14, Kenneth M Saag, MD, MSc1,15, Sean I Savitz, MD16, Kathryn H Schmitz, MPH, PhD17, Jennifer Stevens-Lapsley, PT, PhD18, John Whyte, MD, PhD19, Carolee J Winstein, PT, PhD20, and Mary E Michel, PhD21
Roanoke, VA 24016; 9Virginia C Crawford Research Institute, Shepherd Center, Atlanta, GA 30309 and Division of Physical Therapy, Emory University School of Medicine, Atlanta, GA 30322; 10Division of Preventive Medicine, Department of Medicine and Minority Health and Health Disparities Research Center, University of Alabama at Birmingham, Birmingham, AL 35294; 11Physical Therapy, Occupational Therapy, and Neurology Washington University School of Medicine, St Louis, MO 63108; 12The Emmes Corporation, Rockville, MD 20850; 13Department of Physical Therapy, University of Alabama at
Trang 3Birmingham, Birmingham, AL 35294; 14Department of Physical Therapy, University of Delaware, Newark,
DE 19716; 15Division of Clinical Immunology and Rheumatology, Department of Medicine and Center for Outcomes and Effectiveness Research and Education, University of Alabama at Birmingham,
Birmingham, AL 35294; 16Department of Neurology, University of Texas Health Science Center, Houston,
TX 77030; 17Department of Public Health Sciences, Pennsylvania State University, State College, PA 16801; 18Physical Therapy Program, University of Colorado, Denver, CO 80045; 19Moss Rehabilitation Research Institute, Einstein Medical Center, Philadelphia, PA 19141; 20Division of Biokinesiology and Physical Therapy, University of Southern California, Los Angeles, CA 90089; 21National Center for Medical Rehabilitation Research, National Institutes of Health, Bethesda, MD 20847 (retired)
Acknowledgments: We sincerely thank Dr Alison Cernich, Director, and Dr Ralph Nitkin, Program
Official, for their NCMRR leadership, and for their support of the clinical trials workshop summarized in this manuscript Supported in part by NIH Grant P2CHD086851
Conflicts of Interest: The authors disclose the following relationships:
J Chae discloses a relationship with: SPR Therapeutics
G Cutter discloses relationships with: Pythagoras (Board membership), Amo Pharmaceuticals, Teva Neuroscience, EMD Serono, Novartis, Pfizer, Sanofi, AMO, Genzyme, Medimmune, Receptos, Gilead, Sanofi-Aventis, Apotex/Modigenetec, Opko, NHLBI, NICHD, Ono/Merck, Genentech, GSK,
Transparency Life Sciences, Roche, Ophazyme, Somahlution, Horizon Pharma, Reata Pharma, PTC Therapeutics, Klein-Buendel, Merck/Pfizer, UT Houston, Medday, Roche, Sciflour, Axon, and GW Pharmaceuticals
S Savitz discloses relationships via his institution (UTHealth) with: Athersys, Genentech, Pfizer, Dart Neuroscience, SanBio, Let’s Cure CP, the Texas Institute for Rehabilitation and Research Foundation, Cord Blood Registry Systems, Neuralstem, Mesoblast, BlueRock, ReNeuron, Lumosa, Celgene, Dart Neuroscience, and Aldagen
Word Counts: Main Text = 6159; Online Appendix = 2242
Address for Correspondence: Marcas M Bamman, PhD, UAB Center for Exercise Medicine, 1313 13th
Street South, Room 300, University of Alabama at Birmingham, Birmingham, AL 35205-5327
Phone 205-975-9042, mbamman@uab.edu
Trang 251 Simon R, Maitournam A Evaluating the Efficiency of Targeted Designs for Randomized Clinical
Trials Clinical Cancer Research 2004;10(20):6759-6763
2 Cutter G, Kappos L Clinical trials in multiple sclerosis Handbook of clinical neurology
5 Gomes-Osman J, Cortes M, Guest J, Pascual-Leone A A Systematic Review of Experimental
Strategies Aimed at Improving Motor Function after Acute and Chronic Spinal Cord Injury
Journal of neurotrauma 2016;33(5):425-438
6 Constantini S, Young W The effects of methylprednisolone and the ganglioside GM1 on acute
spinal cord injury in rats Journal of neurosurgery 1994;80(1):97-111
7 Geisler FH, Dorsey FC, Coleman WP Recovery of motor function after spinal-cord injury a
randomized, placebo-controlled trial with GM-1 ganglioside N Engl J Med
1991;324(26):1829-1838
8 Backman CL, Harris SR Case studies, single-subject research, and N of 1 randomized trials:
comparisons and contrasts American journal of physical medicine & rehabilitation
1999;78(2):170-176
9 Senn S Are placebo run ins justified? BMJ 1997;314(7088):1191
10 Senn S, Lee S The analysis of the AB/BA cross-over trial in the medical literature
Pharmaceutical Statistics 2004;3(2):123-131
11 Sackett DL HR, Guyatt GH, Tugwell P Clinical Epidemiology: A Basic Science for Clinical Medicine
2nd ed: Little, Brown & Co; 1991
12 P O Single case designs In: Everitt BS HD, ed Encyclopedia of Statistics in Behavioral Science
Chichester: John Wiley & Sons Ltd; 2005
13 Hawkins NG, Sanson-Fisher RW, Shakeshaft A, D'Este C, Green LW The multiple baseline design
for evaluating population-based research American journal of preventive medicine
2007;33(2):162-168
14 Center for Information and Study on Clinical Research www.ciscrp.org Accessed February 8,
2017
15 DiMasi JA, Grabowski HG, Hansen RW Innovation in the pharmaceutical industry: New
estimates of R&D costs Journal of health economics 2016;47:20-33
16 Institute of M Envisioning a Transformed Clinical Trials Enterprise in the United States:
Establishing an Agenda for 2020: Workshop Summary Washington, DC: The National Academies
Press; 2012
17 Sherman RE, Anderson SA, Dal Pan GJ, et al Real-World Evidence — What Is It and What Can It
Tell Us? New England Journal of Medicine 2016;375(23):2293-2297
18 Schwartz D, Lellouch J Explanatory and pragmatic attitudes in therapeutical trials J Chronic Dis
1967;20(8):637-648
19 Fletcher RH, Fletcher SW, Wagner EH Clinical Epidemiology - the Essentials 2nd ed Baltimore,
MD: Williams & Wilkins; 1988
20 Pincus T, Sokka T Clinical trials in rheumatic diseases: designs and limitations Rheum Dis Clin
North Am 2004;30(4):701-724, v-vi
21 Eapen ZJ, Lauer MS, Temple RJ The imperative of overcoming barriers to the conduct of large,
simple trials JAMA 2014;311(14):1397-1398
Trang 2622 US Department of Health and Human Services, Food and Drug Administration, Center for Drug
Evaluation and Research, Center for Biologics Evaluation and Research Determining the Extent
of Safety Data Collection Needed in Late-Stage Premarket and Postapproval Clinical
Investigations - Guidance for Industry 2016;
http://www.fda.gov/downloads/drugs/guidances/ucm291158.pdf Accessed February 8, 2017
23 Thorpe KE, Zwarenstein M, Oxman AD, et al A pragmatic-explanatory continuum indicator
summary (PRECIS): a tool to help trial designers J Clin Epidemiol 2009;62(5):464-475
24 Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M The PRECIS-2 tool:
designing trials that are fit for purpose BMJ 2015;350:h2147
25 Saag KG, Mohr PE, Esmail L, et al Improving the efficiency and effectiveness of pragmatic clinical
trials in older adults in the United States Contemp Clin Trials 2012;33(6):1211-1216
26 Organization WH International Classification of Functioning, Disability and Health 2001;
http://www.who.int/classifications/icf/en/
27 Hart T, Ehde DM Defining the treatment targets and active ingredients of rehabilitation:
Implications for rehabilitation psychology Rehabil Psychol 2015;60(2):126-135
28 VanHiel LR Treatment and enablement in rehabilitation research Archives of physical medicine
and rehabilitation 2014;95(1 Suppl):S88-90
29 Whyte J Contributions of treatment theory and enablement theory to rehabilitation research
and practice Archives of physical medicine and rehabilitation 2014;95(1 Suppl):S17-23 e12
30 Whyte J, Dijkers MP, Hart T, et al Development of a theory-driven rehabilitation treatment
taxonomy: conceptual issues Archives of physical medicine and rehabilitation 2014;95(1
Suppl):S24-32 e22
31 Bamman MM, Petrella JK, Kim JS, Mayhew DL, Cross JM Cluster analysis tests the importance of
myogenic gene expression during myofiber hypertrophy in humans J Appl Physiol (1985)
2007;102(6):2232-2239
32 Mayhew DL, Hornberger TA, Lincoln HC, Bamman MM Eukaryotic initiation factor 2B epsilon
induces cap-dependent translation and skeletal muscle hypertrophy The Journal of physiology
2011;589(Pt 12):3023-3037
33 Petrella JK, Kim JS, Mayhew DL, Cross JM, Bamman MM Potent myofiber hypertrophy during
resistance training in humans is associated with satellite cell-mediated myonuclear addition: a
cluster analysis Journal of applied physiology 2008;104(6):1736-1742
34 Stec MJ, Kelly NA, Many GM, Windham ST, Tuggle SC, Bamman MM Ribosome biogenesis may
augment resistance training-induced myofiber hypertrophy and is required for myotube growth
in vitro American journal of physiology Endocrinology and metabolism 2016:ajpendo 00486
02015
35 Thalacker-Mercer A, Stec M, Cui X, Cross J, Windham S, Bamman M Cluster analysis reveals
differential transcript profiles associated with resistance training-induced human skeletal muscle
hypertrophy Physiol Genomics 2013;45(12):499-507
36 Stec MJ, Thalacker-Mercer A, Mayhew DL, et al Randomized, four-arm, dose-response clinical
trial to optimize resistance exercise training for older adults with age-related muscle atrophy
Exp Gerontol 2017;99:98-109
37 Long DE, Peck BD, Martz JL, et al Metformin to Augment Strength Training Effective Response in
Seniors (MASTERS): study protocol for a randomized controlled trial Trials 2017;18(1):192
38 Knutson JS, Gunzler DD, Wilson RD, Chae J Contralaterally Controlled Functional Electrical
Stimulation Improves Hand Dexterity in Chronic Hemiparesis: A Randomized Trial Stroke
2016;47(10):2596-2602
39 Kelly NA, Ford MP, Standaert DG, et al Novel, high-intensity exercise prescription improves
muscle mass, mitochondrial function, and physical capacity in individuals with Parkinson's
Trang 27disease Journal of applied physiology 2014;116(5):582-592
40 Corcos DM, Robichaud JA, David FJ, et al A two-year randomized controlled trial of progressive
resistance exercise for Parkinson's disease Mov Disord 2013;28(9):1230-1240
41 McDonald AM, Knight RC, Campbell MK, et al What influences recruitment to randomised
controlled trials? A review of trials funded by two UK funding agencies Trials 2006;7:9
42 Kadam RA, Borde SU, Madas SA, Salvi SS, Limaye SS Challenges in recruitment and retention of
clinical trial subjects Perspect Clin Res 2016;7(3):137-143
43 Frank G Current Challenges In Clinical Trial Patient Recruitment and Enrollment SOCRA Source
2004;2(February):9
44 Shalowitz DI, Miller FG Communicating the results of clinical research to participants: attitudes,
practices, and future directions PLoS Med 2008;5(5):e91
45 Caldwell PH, Hamilton S, Tan A, Craig JC Strategies for increasing recruitment to randomised
controlled trials: systematic review PLoS Med 2010;7(11):e1000368
46 Fouad MN, Acemgil A, Bae S, et al Patient Navigation As a Model to Increase Participation of
African Americans in Cancer Clinical Trials Journal of Oncology Practice 2016;12(6):556-563
47 Fouad MN, Acemgil A, Bae S, et al Patient Navigation As a Model to Increase Participation of
African Americans in Cancer Clinical Trials J Oncol Pract 2016;12(6):556-563
48 Lai B, Young HJ, Bickel CS, Motl RW, Rimmer JH Current Trends in Exercise Intervention
Research, Technology, and Behavioral Change Strategies for People With Disabilities: A Scoping
Review American journal of physical medicine & rehabilitation 2017;96(10):748-761
49 Larkin L, Kennedy N, Gallagher S Promoting physical activity in rheumatoid arthritis: a narrative
review of behaviour change theories Disabil Rehabil 2015;37(25):2359-2366
50 Ellis T, Motl RW Physical activity behavior change in persons with neurologic disorders:
overview and examples from Parkinson disease and multiple sclerosis Journal of neurologic
physical therapy : JNPT 2013;37(2):85-90
51 Adamson BC, Learmonth YC, Kinnett-Hopkins D, Bohri M, Motl RW Feasibility study design and
methods for Project GEMS: Guidelines for Exercise in Multiple Sclerosis Contemp Clin Trials
2016;47:32-39
52 Learmonth YC, Adamson, B C., Kinnett-Hopkins, D., Bohri, M., & Motl, R W Results of a
feasibility randomized controlled study of the guidelines for exercise in multiple sclerosis
project Contemporary Clinical Trials In Press
53 Beidas RS, Paciotti B, Barg F, et al A hybrid effectiveness-implementation trial of an
evidence-based exercise intervention for breast cancer survivors Journal of the National Cancer Institute
Monographs 2014;2014(50):338-345
54 Schmitz KH, Ahmed RL, Troxel A, et al Weight lifting in women with breast-cancer-related
lymphedema N Engl J Med 2009;361(7):664-673
55 Schmitz KH, Ahmed RL, Troxel AB, et al Weight lifting for women at risk for breast
cancer-related lymphedema: a randomized trial Jama 2010;304(24):2699-2705